Lantern Pharma Receives FDA Clearance for Pediatric Cancer Clinical Trial

Lantern Pharma and its subsidiary Starlight Therapeutics have received clearance from the U.S. Food and Drug Administration (FDA) for an Investigational New Drug (IND) application. This approval allows the companies to initiate a Phase 1 clinical trial for STAR-001, a drug candidate designed to treat pediatric Central Nervous System (CNS) cancer. The trial will focus on evaluating the safety and efficacy of the treatment in children with rare brain and CNS tumors. This regulatory milestone marks a significant transition for STAR-001 from preclinical development to human clinical testing. Investors typically view such developments positively, as they validate the company's research pipeline and move the therapy closer to potential commercialization. Shares of Lantern Pharma (LTRN) may see increased activity following this announcement as the company expands its clinical-stage portfolio.

Sources:businesswire.combiospace.comclinicaltrials.govhkexnews.hksecure.instagram.comstocktitan.netinvesting.commarketscreener.comtradingview.comfinancialcontent.com